Back to top

pharmaceuticals: Archive

Kinjel Shah

LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?

Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.

AZNPositive Net Change GSKPositive Net Change JNJPositive Net Change LLYNegative Net Change

Zacks Equity Research

NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity

Novo Nordisk stock rises as its next-generation subcutaneous obesity treatment candidate, cagrilintide, delivers meaningful weight loss in a phase III obesity study.

NVOPositive Net Change LLYNegative Net Change AMGNPositive Net Change VKTXNegative Net Change

Zacks Equity Research

INCY Announces New Late-Stage Data on Skin Disease Drug

Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.

NVSNegative Net Change INCYPositive Net Change ANIPNegative Net Change CRMDNegative Net Change

Kinjel Shah

Vertex Plunges Around 24% in Six Months: How to Play the Stock

Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.

VRTXNegative Net Change MRNAPositive Net Change CRSPNegative Net Change

Mark Vickery

Top Research Reports for Alphabet, IBM & Merck

Alphabet, IBM, and Merck headline Zacks' latest research reports, with insights spanning AI, cloud growth, and pipeline challenges.

IBMPositive Net Change MRKPositive Net Change MUPositive Net Change MFCNegative Net Change SDPositive Net Change GOOGLNegative Net Change CFGPositive Net Change NRXSPositive Net Change

Sundeep Ganoria

AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?

Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.

NVOPositive Net Change LLYNegative Net Change AMGNPositive Net Change VKTXNegative Net Change

Zacks Equity Research

MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer

Merck and Daiichi's raludotatug deruxtecan wins FDA Breakthrough tag for treating CDH6 expressing platinum-resistant ovarian, primary peritoneal or fallopian tube cancers.

AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change

Kinjel Shah

Will GSK Be Able to Resolve Its Vaccine Challenges Anytime Soon?

GSK faces U.S. vaccine sales declines as Shingrix and Arexvy stumble. Penmenvy approval and pipeline efforts may aid long-term growth.

GSKPositive Net Change PFEPositive Net Change MRNAPositive Net Change

Kinjel Shah

Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?

AbbVie surges 22.5% YTD as new drugs Skyrizi and Rinvoq drive growth, offsetting Humira losses and fueling long-term momentum.

NVOPositive Net Change LLYNegative Net Change ABBVPositive Net Change

Zacks Equity Research

Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis

GLUE surges 44% after sealing a $5.7B licensing deal with NVS to advance molecular glue degraders for immune diseases.

NVSNegative Net Change RHHBYPositive Net Change GLUENegative Net Change

Ahan Chakraborty

Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?

Novo Nordisk gains EU approval for adding the cardiovascular indication to Rybelsus' label, strengthening its edge in the competitive diabetes market.

NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change

Tirthankar Chakraborty

The Under $20 Breakout Trio Investors Shouldn't Ignore

Sally Beauty, Broadstone Net Lease and Opus Genetics emerge as today's breakout stock picks under $20, flagged for potential near-term gains.

SBHPositive Net Change BNLNegative Net Change IRDPositive Net Change

Kinjel Shah

Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?

Eli Lilly shares move past the 50-day SMA as weight-loss drug data, rising sales and pipeline momentum fuel optimism.

NVOPositive Net Change LLYNegative Net Change AMGNPositive Net Change VKTXNegative Net Change

Ahan Chakraborty

CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?

CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.

PFEPositive Net Change AMPHNegative Net Change CRMDNegative Net Change

Zacks Equity Research

REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?

Regeneron shares slump as Eylea struggles, but Dupixent gains and a strengthening oncology pipeline offer growth potential.

REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change

Zacks Equity Research

Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain

ZTS secures CVMP's positive opinion recommending the approval of Portela, a long-acting OA pain therapy for cats, with final decision expected in late 2025.

ZTSNegative Net Change CRMDNegative Net Change KNSANegative Net Change PHARPositive Net Change

Sundeep Ganoria

COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths

MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.

PFEPositive Net Change MRNAPositive Net Change NVAXNegative Net Change BNTXNegative Net Change

Zacks Equity Research

JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra

J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.

JNJPositive Net Change ANIPNegative Net Change CRMDNegative Net Change PTGXPositive Net Change

Zacks Equity Research

RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal

Rapport Therapeutics stock jumps 62% in a week as mid-stage study of RAP-219 meets goals in drug-resistant epilepsy patients.

CRMDNegative Net Change KNSANegative Net Change PHARPositive Net Change RAPPPositive Net Change

Zacks Equity Research

OLMA Stock Soars 47% in September So Far on Second PFE Deal

Olema Pharmaceuticals surges 47% in September after striking a second collaboration with Pfizer for its lead breast cancer product candidate, palazestrant.

AZNPositive Net Change NVSNegative Net Change PFEPositive Net Change OLMANegative Net Change

Kinjel Shah

Pfizer's Late-Stage Pipeline Fuels Long-Term Growth Prospects

Pfizer's late-stage pipeline, from oncology blockbusters to mRNA vaccines, positions it for long-term growth despite recent setbacks.

AZNPositive Net Change BMYNegative Net Change PFEPositive Net Change MRKPositive Net Change

Sundeep Ganoria

AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock

ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.

JNJPositive Net Change LLYNegative Net Change ABBVPositive Net Change

Ekta Bagri

BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?

Bristol Myers and BioNTech report strong mid-stage lung cancer trial data for pumitamig, showing high response rates and manageable safety.

BMYNegative Net Change PFEPositive Net Change MRKPositive Net Change BNTXNegative Net Change

Ekta Bagri

Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?

Black Diamond sharpens focus on silevertinib after outlicensing BDTX-4933, cutting costs, and securing cash runway into late 2027.

AZNPositive Net Change JNJPositive Net Change BDTXNegative Net Change

Zacks Equity Research

The Zacks Analyst Blog Highlights Oracle, AstraZeneca, Shopify and Blue Ridge Bankshares

Oracle, AstraZeneca, Shopify, and Blue Ridge Bankshares show strong growth and strategic market opportunities.

AZNPositive Net Change ORCLNegative Net Change SHOPPositive Net Change BRBSNegative Net Change